Novo Nordisk's Weight-Loss Pill Faces a Price Hike and a New Rival

Novo Nordisk hikes US price for oral Wegovy, faces new rival Foundayo, and gets UK approval for a higher-dose single-injector pen. Stock remains under pressure.

Novo Nordisk's strategy for its oral weight-loss drug Wegovy is entering a critical new phase. The company is raising the U.S. introductory price for the pill just as a formidable competitor, Eli Lilly's Foundayo, enters the market. This dual challenge arrives alongside a key regulatory approval in the UK, creating a complex backdrop for the Danish pharmaceutical giant.

Starting April 15, the monthly cost for the 4-milligram dose of Wegovy's oral version will increase from $149 to $199. Higher dosage strengths will remain priced at $299. Novo Nordisk had used the lower entry price to capture market share and attract patients with needle phobia since the pill's launch in January, a tactic that generated over 600,000 prescriptions. The price hike tests whether this early patient demand can be sustained.

The competitive landscape intensified simultaneously with the U.S. Food and Drug Administration's approval of Eli Lilly's rival pill, Orforglipron, branded as Foundayo. It will be available in the same Amazon pharmacy kiosks as Wegovy. Foundayo holds a key convenience advantage: patients face no dietary or fasting requirements. In contrast, Wegovy's oral version must be taken on an empty stomach followed by a 30-minute wait. Novo Nordisk counters by pointing to older clinical data suggesting its pill delivers a higher average weight loss.

Regulatory Progress and AI Ambitions

Amid this commercial pressure, Novo Nordisk secured a regulatory win in the United Kingdom. The Medicines and Healthcare products Regulatory Agency approved a new single-injection device for Wegovy's highest available dose of 7.2 mg. Previously, patients required three separate 2.4 mg injections weekly. Clinical data from the STEP-UP study supports the higher dose, showing an average weight loss of 18.7% compared to 3.9% for a placebo. With full adherence, that figure rose to 20.7% after 72 weeks, with one-third of participants losing 25% or more of their body weight.

The new single-use pen targets patients who haven't met their goals on the standard 2.4 mg dose. Novo Nordisk expects UK stock to be available within four to six weeks. On the same day as this announcement, the company revealed a partnership with OpenAI to integrate artificial intelligence across its research, production, and commercial operations, targeting full implementation by year-end.

Market Skepticism and Technical Signals

These developments provided a modest lift to the stock, which gained around four percent to trade at 33.48 euros. However, this uptick is set against a stark longer-term decline. Year-to-date, the share price has fallen nearly 26%, and it remains roughly 52% below its 12-month high of 70.13 euros. The Relative Strength Index, sitting at a low of around 20, indicates a technically oversold condition that has yet to spark a sustained recovery.

Analyst sentiment reflects the operational uncertainty. BMO Capital Markets reduced its price target for Novo Nordisk from $45 to $36, maintaining a "Market Perform" rating. The firm forecasts first-quarter 2026 sales for the Wegovy pill at 881 million Danish kroner, roughly 12% below consensus estimates of over one billion kroner.

Upcoming Catalysts and Strategic Moves

All eyes are now on May, when Novo Nordisk reports its Q1 2026 results. This release will offer the first concrete evidence of whether strong prescription volumes can offset pricing pressures and competitive incursions in the US market. A separate, ongoing share buyback program continues in the background. Since February 2026, the company has repurchased shares worth approximately 2.84 billion Danish kroner as part of a broader program authorized for up to 15 billion kroner.

The next major pipeline catalyst is the anticipated FDA decision on CagriSema, a combination therapy of cagrilintide and semaglutid, expected around the turn of the year 2026/2027. A positive verdict there could provide a decisive boost in Novo Nordisk's high-stakes race with Eli Lilly. For now, the company must prove its weight-loss franchise can bear the weight of higher prices and sharper competition.